Table 1 Patient characteristics
From: Impact of renin-angiotensin system inhibitors on the survival of patients with rectal cancer
Total number of patients (n = 242) | ACEI n = 123 | ARB n = 35 | p | RASI n = 158 | Non-RASI n = 84 | p | ||
|---|---|---|---|---|---|---|---|---|
Age | median (IQR) | 68 (62–73) | 69 (63–74) | 67(60.5–69.5) | 0.074 | 68 (62–74) | 67 (61–72) | 0.460 |
Sex | Females | 109 (45.04%) | 53 (43.09%) | 21 (60.00%) | 0.087 | 74 (46.84%) | 35 (41.67%) | 0.498 |
Males | 133 (54.96%) | 70 (56.91%) | 14 (40.00%) | 84 (53.16%) | 49 (58.33%) | |||
BMI | median (IQR) | 26.8 (24.6–30.475) | 26.8 (24.75–29.82) | 28.4 (25.75–30.95) | 0.083 | 27(24.92–30.575) | 26.4 (24.575–30.4) | 0.420 |
CAD | Yes | 52 (21.49%) | 25 (20.33%) | 5 (14.29%) | 0.476 | 30 (18.99%) | 22 (26.19%) | 0.250 |
No | 190 (78.51%) | 98 (79.67%) | 30 (85.71%) | 128 (81.01%) | 62 (73.81%) | |||
DM | Yes | 70 (28.93%) | 35 (28.46%) | 12 (34.29%) | 0.533 | 47 (29.75%) | 23 (27.38%) | 0.767 |
No | 172 (71.07%) | 88 (71.54%) | 23 (65.71%) | 111 (70.25%) | 61 (72.62%) | |||
CKD | Yes | 6 (2.48%) | 2 (1.63%) | 1 (2.86%) | 0.531 | 3 (3.57%) | 3 (1.90%) | 0.421 |
No | 236 (97.52%) | 121 (98.37%) | 34 (97.14%) | 81 (96.43%) | 155 (98.10%) | |||
CCI | 0–2 | 123 (50.83) | 61 (49.59%) | 18 (51.43%) | 1 | 79 (50.00%) | 44 (52.38%) | 0.787 |
> 2 | 119 (49.17) | 62 (50.41%) | 17 (48.57%) | 79 (50.00%) | 40 (47.62%) | |||
cTNM Stage | 2 | 73 (30.17) | 37 (30.08%) | 16 (45.71%) | 0.105 | 53 (33.54%) | 20 (23.81%) | 0.141 |
3 | 169 (69.83) | 86 (69.92%) | 19 (54.29%) | 105 (66.46%) | 64 (76.19%) | |||
Distance to the anal verge | < = 5 cm | 138 (57.02%) | 76 (61.79%) | 17 (48.57%) | 0.350 | 93 (58.86%) | 45 (53.57%) | 0.663 |
6–10 cm | 69 (28.51%) | 32 (26.02%) | 12 (34.29%) | 44 (27.85%) | 25 (29.76%) | |||
11–15 cm | 35 (14.46%) | 15 (12.20%) | 6 (17.14%) | 21 (13.29%) | 14 (16.67%) | |||
Neo-adjuvant | RT | 178 (73.55%) | 93 (75.61%) | 25 (71.43%) | 0.661 | 118 (74.68%) | 60 (71.43%) | 0.647 |
CRT | 64 (26.45%) | 30 (24.39%) | 10 (28.57%) | 40 (25.32%) | 24 (28.57%) | |||
Surgery | AR | 135 (55.79%) | 67 (54.47%) | 19 (54.29%) | 1 | 86 (54.43%) | 49 (58.33%) | 0.237 |
APR | 96 (39.67%) | 52 (42.28%) | 15 (42.86%) | 67 (42.41%) | 29 (34.52%) | |||
Hartm | 11 (4.55%) | 4 (3.25%) | 1 (2.86%) | 5 (3.16%) | 6 (7.14%) | |||
Clavien | 0–2 | 204 (84.30%) | 107 (86.99%) | 33 (94.29%) | 0.366 | 140 (88.61%) | 64 (76.19%) | 0.015 |
> 2 | 38 (15.70%) | 16 (13.01%) | 2 (5.71%) | 18 (11.39%) | 20 (23.81%) | |||
ypT | 0–1 | 25 (10.33%) | 9 (7.32%) | 4 (11.43%) | 0.454 | 13 (8.23%) | 12 (14.29%) | 0.143 |
2 | 86 (35.54%) | 51 (41.46%) | 11 (31.43%) | 62 (39.24%) | 24 (28.57%) | |||
3–4 | 131 (54.13%) | 63 (51.22%) | 20 (57.14%) | 83 (52.53%) | 48 (57.14%) | |||
ypN | positive | 91 (37.60%) | 43 (34.96%) | 14 (40.00%) | 0.690 | 57 (36.08%) | 34 (40.48%) | 0.577 |
negative | 151 (62.40%) | 80 (65.04%) | 21 (60.00%) | 101 (63.92%) | 50 (59.52%) | |||
LNY | median (IQR) | 11.5 (8–16) | 12 (8–16) | 11 (7.5–15.5) | 0.620 | 11.5 (8–16) | 11.5 (8–16) | 0.666 |
TRG | 0–1 | 88 (36.36%) | 40 (32.52%) | 9 (25.71%) | 0.537 | 49 (31.01%) | 39 (46.43%) | 0.024 |
2–3 | 154 (63.64%) | 83 (67.48%) | 26 (74.29%) | 109 (68.99%) | 45 (53.57%) | |||
LVI | Yes | 8 (3.31%) | 6 (2.50%) | 0 (0.00%) | 0.340 | 6 (3.80%) | 2 (2.38%) | 0.717 |
No | 234 (96.69%) | 117 (97.50%) | 35 (100%) | 152 (96.20%) | 82 (97.62%) | |||
PNI | Yes | 9 (3.72%) | 4 (3.25%) | 1 (2.86%) | 1 | 5 (3.16%) | 4 (4.76%) | 0.503 |
No | 233 (96.28%) | 119 (96.75%) | 34 (97.14%) | 153 (96.84%) | 80 (95.24%) | |||
Adjuvant CT | Yes | 81 (33.47%) | 41 (33.33%) | 12 (34.29%) | 1 | 53 (33.54%) | 28 (33.33%) | 1 |
No | 161 (66.53%) | 82 (66.67%) | 23 (65.71%) | 105 (66.46%) | 56 (66.67%) | |||
Adjuvant CT > 3 cycles | Yes | 73 (30.17%) | 35 (28.46%) | 13 (37.14%) | 0.405 | 48 (30.38%) | 25 (29.76%) | 1 |
No | 169 (69.83%) | 88 (71.54%) | 22 (62.86%) | 110 (69.62%) | 59 (70.24%) | |||
CT cycles | Median (IQR) | 1 (0–4.75) | 1 (0–4) | 0 (0–6) | 0.711 | 0.5 (0–4) | 1 (0–5.25) | 0.480 |